Nalfurafine (trade name - Nalfon) is an orally active, non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation in adults and children. It is a member of the fenamate class of drugs, and acts by inhibiting the activity of cyclooxygenase-2 (COX-2) enzymes, which are responsible for the production of prostaglandins, substances associated with pain and inflammation. Nalfurafine is approved for use in the United States, and is available in oral tablets, capsules, and liquid formulations. Nalfurafine hydrochloride is a medication used to treat pruritus, or itching, caused by chronic kidney disease (CKD). It is a non-opioid analgesic and is believed to work by blocking the release of chemical substances that cause itching. Nalfurafine has been approved by the FDA for use in adults with CKD to reduce itching associated with the condition. It has been found to be effective in reducing the intensity and duration of itching in patients with CKD. Nalfurafine is available in tablet form and is usually taken twice daily. It is important to take nalfurafine exactly as prescribed by your doctor, as taking too much can cause serious side effects.
Nalfurafine is a prescription medication sold under the brand name Remitch that is specifically used to treat severe itching, also known as pruritus, in people with chronic kidney disease who are undergoing hemodialysis . It works by activating the kappa-opioid receptors in the central nervous system, which helps to block the sensation of itch.
Nalfurafine is the first medication approved for clinical use that selectively targets these kappa-opioid receptors. It is considered a major development in the treatment of uremic pruritus, a condition that can significantly impact the quality of life for patients with chronic kidney disease.